Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits

British Journal of Pharmacology
H MitaniS Hayashi

Abstract

1. The effects of fluvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on the vascular angiotensin converting enzyme (ACE) activity in hyperlipidaemic rabbits were compared with those of enalapril, an ACE inhibitor. 2. Rabbits were fed a 1.5% cholesterol containing diet or normal diet for 16 weeks and treated with either fluvastatin or enalapril in the diet at the respective doses of 2 and 10 mg kg-1 day-1. The total cholesterol, triglyceride and phospholipid levels in serum were significantly increased in rabbits fed the high cholesterol diet. Treatment with fluvastatin but not enalapril resulted in a decrease in serum lipids. 3. The vascular ACE activities assessed via the cleavage rate from synthetic substrate in the aortic arches and upper thoracic aortae were increased by 8 to 10 times when the rabbits were made hyperlipidaemic. Fluvastatin as well as enalapril significantly lowered the tissue ACE in the aortae. 4. The ACE activities in serum did not alter in hyperlipidaemic rabbits either in the presence or absence of fluvastatin. The serum ACE activity was lowered by enalapril. 5. The lipid peroxide in serum as well as the plaque area in the thoracic aorta was significantly increased in...Continue Reading

References

Jan 1, 1990·Journal of Cardiovascular Pharmacology·G Aberg, P Ferrer
Oct 1, 1991·Hypertension·W OsterriederH R Baumgartner
Jan 1, 1993·Journal of Cardiovascular Pharmacology·V J Dzau
Sep 1, 1995·Arteriosclerosis, Thrombosis, and Vascular Biology·F BerniniR Fumagalli
Jan 1, 1995·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A CorsiniA L Catapano
Jun 6, 1994·The American Journal of Medicine·M H Davidson
Apr 1, 1993·The Journal of Clinical Investigation·J R SchuhE H Blaine

❮ Previous
Next ❯

Citations

Dec 2, 2009·Current Heart Failure Reports·Helene Glassberg
Aug 12, 1999·European Journal of Pharmacology·H BultK E Matthys
Oct 22, 2002·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·A ImaedaT Yoshikawa
Sep 12, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hironobu MitaniMasaaki Kimura
Nov 24, 1999·Clinical and Experimental Pharmacology & Physiology·J D LuoX Chen
Jun 1, 2000·Clinical and Experimental Pharmacology & Physiology·S KagotaM Kunitomo
Jun 29, 2013·Vascular Health and Risk Management·Kwadwo Osei BonsuDaniel Diamond Reidpath
May 23, 2001·Clinical Pharmacokinetics·C D Scripture, J A Pieper
Mar 16, 2004·Current Rheumatology Reports·Elisa Y Rhew, Walter G Barr
Apr 25, 2008·Heart Failure Clinics·Amit Kumar, Christopher P Cannon
Dec 18, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·B ShuaiJ H Rong
Jan 11, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·A Corsini
Nov 5, 2004·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Justein Sn SimAllan D Struthers
Aug 1, 1997·Arteriosclerosis, Thrombosis, and Vascular Biology·M KimuraD N Granger
Jan 1, 2005·Toxicology Mechanisms and Methods·Jerzy Beltowski
Feb 26, 2014·Molecular Medicine Reports·Yongtao ZhangChunsheng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.